Monday, December 31, 2018

Shilpa Medicare gets USFDA nod for cancer treatment injection

Shilpa Medicare gets USFDA nod for cancer treatment injection The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.

from Moneycontrol Business News http://bit.ly/2QeZD2x
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Short-term volatility may persist, but FII flows and economic activity to keep sentiment positive: Vikas Khemani

Vikas Khemani of Carnelian Asset Management remains optimistic about Indian markets, citing a strong domestic growth story and the resolutio...